Medical Search

Medical News from FDA US Food & Drug

FDA warns of potential contamination in multiple brands of drugs, dietary supplements

August 11, 2017, 12:34 pm by FDA US Food & Drug

The U.S. Food and Drug Administration is advising consumers and health care professionals not to use any liquid drug or dietary supplement products manufactured by PharmaTech LLC of Davie, Florida, and labeled by Rugby Laboratories, Major Pharmaceuticals and Leader Brands, due to potential contamination with the bacteria Burkholderia cepacia (B. cepacia) and the risk for severe patient infection.


Featured Medical Stories

Newest Fitbits

Have you seen the NEW FITBIT??

Fitbit is now a health tracker and fasion statement. See all the new beautiful models here >> See the HOTTEST new Fitbits!

See the HOT Fitbit Blaze Now Compare All Fitbit Products Google Fitbit
Sense Sleep Tracker

Awaken Your Sleeping Beauty With This Sleep Tracker

Sleep is the new hot topic and from what science tells us, it is the holy grail of health. If you can track it, you can optimize it. If you can optimize it, you can benefit from it. This hot new sleep tracker by Hello is the perfect sleep tracker for the perfect price. There is beauty in health, and it needs to be awakened. But before that, let's get the best sleep of our lives. Learn more here: Sense Sleep Tracker on Amazon

Sleep Tracker on Amazon Sleep Tracker Reviews Google Sleep Trackers

More medical news from FDA US Food & Drug

FDA provides new tools for the development and proper evaluation of tests for detecting Zika virus infection
FDA US Food & Drug : August 17, 2017, 12:52 pm
As an additional measure in the fight against Zika virus, today the U.S. Food and Drug Administration announced that it has made available a panel of human plasma samples to aid in the regulatory evaluation of serological tests to detect recent Zika virus infection.

FDA approves new treatment for adults with relapsed or refractory acute lymphoblastic leukemia
FDA US Food & Drug : August 17, 2017, 10:22 am
The U.S. Food and Drug Administration today approved Besponsa (inotuzumab ozogamicin) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

FDA warns of potential contamination in multiple brands of drugs, dietary supplements
FDA US Food & Drug : August 11, 2017, 12:34 pm
The U.S. Food and Drug Administration is advising consumers and health care professionals not to use any liquid drug or dietary supplement products manufactured by PharmaTech LLC of Davie, Florida, and labeled by Rugby Laboratories, Major Pharmaceuticals and Leader Brands, due to potential contamination with the bacteria Burkholderia cepacia (B. cepacia) and the risk for severe patient infection.

FDA to expand public education campaign to focus on prevention of youth e-cigarette use
FDA US Food & Drug : August 8, 2017, 7:00 am
Today, the U.S. Food and Drug Administration announced it would pursue a strategic, new public health education campaign aimed at discouraging the use of e-cigarettes and other electronic nicotine delivery systems (ENDS) by kids. The agency plans to expand its “The Real Cost” public education campaign to include messaging to teens about the dangers of using these products this fall while developing a full-scale campaign to launch in 2018. These efforts are part of the agency’s new comprehensive plan for tobacco and nicotine regulation, as well as ongoing efforts to educate youth about, and protect them from, the dangers associated with using all tobacco products. It is the first time the FDA will be utilizing public health education to specifically target youth use of e-cigarettes or other ENDS.

Federal judge enters consent decree against outsourcing facility Isomeric Pharmacy Solutions
FDA US Food & Drug : August 4, 2017, 7:17 am
U.S. District Judge Robert J. Shelby entered a consent decree of permanent injunction yesterday between the United States and Isomeric Pharmacy Solutions of Salt Lake City, Utah, two of the company’s co-owners, William O. Richardson and Rachael S. Cruz, and chief operating officer Jeffery D. Brown.